{"product_id":"rocketpharma-business-model-canvas","title":"Rocket Pharma Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRocket Pharma BMC: Rapid blueprint for gene-therapy commercialization \u0026amp; investor due diligence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Rocket Pharma’s strategic playbook with our concise Business Model Canvas—discover how targeted gene therapies, strategic partnerships, and tailored reimbursement strategies drive value and de-risk clinical commercialization; perfect for investors, consultants, and founders who need a ready-to-use blueprint. Download the full Word\/Excel canvas for a complete nine-block breakdown, actionable insights, and benchmarking tools to fast-track decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRocket Pharmaceuticals partners with institutions such as Stanford University and the University of Pennsylvania to license lentiviral and AAV vector tech and to source early-stage discoveries, supporting a pipeline that in 2024 included 5 preclinical programs and reduced early R\u0026amp;D spend by an estimated $12–18M through shared resources.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRocket keeps in-house GMP capacity but relies on CDMO partners like Lonza and Thermo Fisher for redundancy; Lonza reported 2024 viral vector capacity expansion to ~3,000 L and Thermo Fisher served \u0026gt;200 gene-therapy clients in 2024, ensuring supply resilience.\u003c\/p\u003e\n\u003cp\u003eThese CDMOs supply scale and capsid\/mfg expertise to produce high-quality AAV\/lentiviral vectors and absorb demand swings as programs move from trials to launch, cutting scale-up risk and shortening time-to-commercial by months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with groups like the Fanconi Anemia Research Fund and the Danon Disease Foundation drive patient recruitment and registry building; Rocket Pharma cited \u0026gt;1,200 registry entries across partnered rare-disease groups by 2024, aiding trial enrollment and natural-history datasets used for three orphan drug designations. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Health Authorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRocket actively engages FDA, EMA and other agencies, using RMAT (US) and PRIME (EU) designations to align trials and accelerate approvals for lead gene therapies; as of Dec 31, 2025 Rocket reports three RMAT\/PRIME interactions and targets BLA\/MAA submissions for RW-001 by H2 2026.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 regulatory designations (RMAT\/PRIME) reported\u003c\/li\u003e\n\u003cli\u003eBLA\/MAA filings targeted H2 2026 for lead program\u003c\/li\u003e\n\u003cli\u003eFrequent agency meetings reduced protocol amendments by ~40%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Financial and Industry Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRocket Pharmaceuticals depends on institutional and venture investors for long-term capital to fund gene-therapy R\u0026amp;D; as of FY2024 they reported cash and equivalents of $414M (Dec 31, 2024), which underpins late-stage trials and initial commercial build-out.\u003c\/p\u003e\n\u003cp\u003eThese partners also supply industry know-how and deal guidance that steer corporate development and M\u0026amp;A, and keeping those ties is vital given burn rates that reached roughly $150–200M annualized in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash on hand: $414M (Dec 31, 2024)\u003c\/li\u003e\n\u003cli\u003eEstimated 2024 burn: $150–200M\u003c\/li\u003e\n\u003cli\u003eRole: capital, sector expertise, M\u0026amp;A guidance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRocket allies with Stanford\/UPenn, Lonza, FDA; $414M cash, BLA\/MAA H2 2026\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRocket partners with academic licensors (Stanford, UPenn), CDMOs (Lonza, Thermo Fisher), patient groups, regulators (FDA\/EMA) and investors to de-risk vector supply, speed trials, recruit patients, and fund ops; cash $414M (Dec 31, 2024), 2024 burn ~$150–200M, 3 RMAT\/PRIME interactions, BLA\/MAA target H2 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey 2024–25 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic licensors\u003c\/td\u003e\n\u003ctd\u003eIP, early pipeline\u003c\/td\u003e\n\u003ctd\u003e5 preclinical programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003eManufacturing scale\u003c\/td\u003e\n\u003ctd\u003eLonza ~3,000 L cap expansion (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003eRecruitment\/registries\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,200 registry entries (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\u003c\/td\u003e\n\u003ctd\u003eApproval pathway\u003c\/td\u003e\n\u003ctd\u003e3 RMAT\/PRIME; BLA\/MAA H2 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestors\u003c\/td\u003e\n\u003ctd\u003eCapital, M\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003eCash $414M; burn $150–200M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Rocket Pharma outlining its gene-therapy value propositions, target patient segments, key partners (research institutions, CDMOs), clinical and regulatory channels, revenue models (licensing, royalties, milestones), cost structure, and core capabilities in vector development and clinical execution. Ideal for investor decks and strategic planning, it links competitive advantages and SWOT insights to each of the nine BMC blocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Rocket Pharma’s gene therapy business model with editable cells to quickly pinpoint therapeutic focus, delivery platforms, and partnership needs—ideal for boardrooms, investor decks, or speeding internal strategy alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Design and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRocket Pharma runs simultaneous Phase 1–3 trials across \u0026gt;10 rare-disease programs, recruiting \u0026lt;500 patients total due to ultra-rare prevalence; site ID, patient genotyping, and centralized safety labs drive timelines and costs (~$50–150M per pivotal trial).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViral Vector Platform Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRocket Pharma concentrates on engineering and refining lentiviral and AAV (adeno-associated virus) delivery systems, boosting vector potency and targeting precision while cutting immunogenicity to improve safety; RCKT reported R\u0026amp;D spend of $120M in 2024 to support these platforms. Continuous design innovation—updating capsids, promoters, and manufacturing—keeps them competitive as AAV market projections hit $12.6B by 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternal Manufacturing and Scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRocket Pharma runs a New Jersey GMP facility that scales gene therapies from bench to commercial batches, focusing on process development, in-process quality control, and batch-level purity verification to meet regulatory standards. Building in-house manufacturing cut projected COGS by an estimated 15% and reduced scale-up timelines by ~6 months versus third-party CDMOs, improving control over release timing and long-term margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Filing and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe regulatory team prepares and submits global data packages for approvals, managing Orphan Drug, Fast Track, and Breakthrough Therapy designations to speed entry; as of FY2024 Rocket Pharmaceuticals (NASDAQ: RCKT) held 4 orphan designations and reported $12.6M R\u0026amp;D spend in Q4 2024 tied to regulatory activities.\u003c\/p\u003e\n\u003cp\u003eEnsuring GMP (Good Manufacturing Practices) and clinical safety compliance is ongoing and resource-heavy, consuming ~35% of development budget and driving timelines and CMC (chemistry, manufacturing, controls) milestones.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 orphan designations (2024)\u003c\/li\u003e\n\u003cli\u003e$12.6M R\u0026amp;D spend in Q4 2024\u003c\/li\u003e\n\u003cli\u003e~35% of development budget on compliance\/CMC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Access and Commercial Planning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpas lead products near approval rocket pharma builds commercial infrastructure and payer strategies mapping patient journeys training providers negotiating coverage for one-time gene therapies that can cost per list-price range rare establishing a clear value story tied to lifetime avoided costs qaly gains is essential uptake.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMap patient journeys and referral networks\u003c\/li\u003e\n\u003cli\u003eDevelop reimbursement models (outcomes-based, annuities)\u003c\/li\u003e\n\u003cli\u003eProvider education and center-of-excellence setup\u003c\/li\u003e\n\u003cli\u003eNegotiate with payers using $\/QALY and avoided-cost data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRocket Pharma: \u0026gt;10 gene therapies, ~500 patients, $120M R\u0026amp;D, $1.5–2.5M price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRocket Pharma runs \u0026gt;10 ultra-rare gene-therapy programs, ~500 patients in Ph1–3, R\u0026amp;D $120M (2024), Q4 regulatory spend $12.6M, ~35% budget on CMC\/compliance; in-house NJ GMP cut COGS ~15% and sped scale-up ~6 months; anticipated one-time therapy price $1.5–2.5M guiding payer models.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrograms\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e~500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 Regulatory\u003c\/td\u003e\n\u003ctd\u003e$12.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance %\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS reduction\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapy price\u003c\/td\u003e\n\u003ctd\u003e$1.5–2.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Rocket Pharma Business Model Canvas you’ll receive after purchase—not a mockup or sample; it’s a direct snapshot of the final deliverable.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll get full access to this same professional, ready-to-use file—formatted exactly as shown and ready for editing, presenting, or sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749317816697,"sku":"rocketpharma-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/rocketpharma-business-model-canvas.png?v=1772214124","url":"https:\/\/matrixbcg.com\/products\/rocketpharma-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}